Abeona Therapeutics Inc vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.41. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| ABEO | YMAG | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $7.45 | $15.98 |
52-Week Low | $4.17 | $10.76 |
Enterprise Value | $276.10M | — |
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →